CASI Pharmaceuticals, Inc. Ordinary Shares (CASI)

Price$0.00

Value ScoreB

Growth ScoreA

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-95.90%

Price vs S&P 500 (4W)-80.09%

VGM Score53.04

Market Capitalization$2.49M

All Metrics

Book Value / Share (Quarterly)$0.12

P/TBV (Annual)23.51x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-1.84%

Cash Flow / Share (Quarterly)$-1.98

Price vs S&P 500 (YTD)-80.06%

Gross Margin (TTM)56.62%

Net Profit Margin (TTM)-129.05%

EPS (TTM)$-2.81

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-2.81

Revenue Growth (5Y)47.19%

EPS (Annual)$-2.56

Dividend / Share (Annual)$0.05

ROI (Annual)-194.00%

Gross Margin (Annual)55.88%

Net Profit Margin (5Y Avg)-140.95%

Cash / Share (Quarterly)$0.45

Revenue Growth QoQ (YoY)83.04%

ROA (Last FY)-73.14%

Revenue Growth TTM (YoY)8.39%

EBITD / Share (TTM)$-2.40

ROE (5Y Avg)-477.65%

Operating Margin (TTM)-129.26%

Cash Flow / Share (Annual)$-1.90

P/B Ratio1.34x

P/B Ratio (Quarterly)20.49x

Net Income / Employee (Annual)$-168,500

EV / Revenue (TTM)0.69x

Net Interest Coverage (TTM)-184.30x

ROA (TTM)-98.39%

EPS Incl Extra (Annual)$-2.56

Current Ratio (Annual)1.09x

Quick Ratio (Quarterly)0.31x

3-Month Avg Trading Volume0.16M

52-Week Price Return-93.00%

Revenue / Employee (TTM)$134,600

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)0.09x

Asset Turnover (Annual)0.53x

52-Week High$3.09

Operating Margin (5Y Avg)-155.92%

EPS Excl Extra (Annual)$-2.56

CapEx CAGR (5Y)-55.67%

Tangible BV CAGR (5Y)-50.83%

26-Week Price Return-93.83%

Quick Ratio (Annual)0.86x

13-Week Price Return-83.08%

Total Debt / Equity (Annual)9.93x

Current Ratio (Quarterly)0.47x

Enterprise Value$21.49M

Revenue / Share Growth (5Y)34.01%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)-56.26%

Revenue / Employee (Annual)$122,500

Inventory Turnover (Annual)1.19x

Pretax Margin (Annual)-133.40%

Cash / Share (Annual)$1.04

3-Month Return Std Dev185.46%

Gross Margin (5Y Avg)54.79%

Net Income / Employee (TTM)$-199,600

ROE (Last FY)-2120.91%

Net Interest Coverage (Annual)-13.09x

EPS Basic Excl Extra (Annual)$-2.56

P/FCF (TTM)2.63x

Receivables Turnover (TTM)4.66x

Total Debt / Equity (Quarterly)9.93x

EPS Incl Extra (TTM)$-2.81

Receivables Turnover (Annual)2.29x

ROI (TTM)-136.86%

P/S Ratio (TTM)0.08x

Pretax Margin (5Y Avg)-146.09%

Revenue / Share (Annual)$1.86

Tangible BV / Share (Annual)$0.10

Price vs S&P 500 (52W)-113.10%

Year-to-Date Return-82.94%

5-Day Price Return-30.95%

EPS Normalized (Annual)$-2.56

ROA (5Y Avg)-39.84%

Net Profit Margin (Annual)-137.57%

Month-to-Date Return-36.71%

Cash Flow / Share (TTM)$-2.14

EBITD / Share (Annual)$-2.58

Operating Margin (Annual)-138.84%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-83.50%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.81

P/TBV (Quarterly)23.51x

P/B Ratio (Annual)20.49x

Inventory Turnover (TTM)1.53x

Pretax Margin (TTM)-125.26%

Book Value / Share (Annual)$0.12

Price vs S&P 500 (13W)-80.04%

Beta0.75x

Revenue / Share (TTM)$2.02

ROE (TTM)-390.77%

52-Week Low$0.05

vGradeB

gGradeA

mGradeF

vgmGradeC

Show chart for

Earnings Surprise History

Q4 25-0.80est. -0.37

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

About

CASI Pharmaceuticals is a specialized biopharmaceutical company focused on oncology therapies for hematologic malignancies including leukemia, lymphoma, and multiple myeloma. The company's marketed products include EVOMELA, a conditioning agent for autologous stem cell transplant in multiple myeloma patients, along with MARQIBO and ZEVALIN. EVOMELA is the primary revenue driver.